Diatide aims to commercialise lung imaging agent:
This article was originally published in Clinica
Executive Summary
Diatide is licensing technology from Merck on a non-exclusive basis to assist in commercialising its pulmonary embolism imaging agent, P748. The product is in Phase II trials. Londonderry, New Hampshire-based Diatide has one FDA-approved product, AcuTect, for scintigraphic imaging of acute venous thrombosis in the lower extremities and has a pipeline of products for specific disease states, based on high affinity radio-labelled peptides.